Notícias

With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, uptapped value” by repurposing drugs

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

The smart money on Pfizer (NYSE: PFE) is sending a quieter signal than the financial press typically rewards: institutional analysts are constructive, insiders are not transacting in size in either direction, and the dividend yield is doing the heavy lifting. With shares at $26.21 and a Wall Street consensus target of $29.19, the absence of ... Insiders Aren’t Buying Pfizer Stock at $26 and That’s Actually a Good Thing

Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.

ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.

BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.

PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.

Pfizer Inc. (NYSE:PFE) ranks among the best retirement stocks to buy now. On May 5, BofA Securities boosted its price objective for Pfizer Inc. (NYSE:PFE) to $27 from $26, retaining a Neutral rating on the company shares. Following Pfizer’s first-quarter performance, the firm raised its fiscal 2026 revenue and earnings per share forecasts. The pharmaceutical […]

These three dividend stocks combine strong yields with resilient businesses.

With $14.2bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not ... If Viking Therapeutics Is Acquired, Here’s Who Wins

Pfizer Inc. (NYSE:PFE) is one of the best medical stocks to invest in according to billionaires. Pfizer Inc. (NYSE:PFE) announced on May 20 data from its Phase 2 study evaluating the safety, tolerability, and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidate PF-07872412 in infants compared to four doses of […]

With the market coming into a seasonally weak time of year, Bear Call Spreads could be an interesting trade to consider.

The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies.

Pfizer’s implied fair value per share has edged up from US$29.08 to US$29.19, while some price targets on the stock cluster around US$26 and into the low to mid US$30s. This reflects a split view across Wall Street, with some analysts leaning on product exclusivity and pipeline potential, and others stressing the US$15b to US$20b revenue cliff and limited visibility on future catalysts. As you read on, you will see how these moving targets shape the evolving analyst story around Pfizer and...

The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.

More CEOs use AI to make business decisions than you might think.

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

The pharma giant is taking steps to expand its portfolio.

iShares Select Dividend ETF (NASDAQ:DVY) is one of the older income-focused funds on the market. The question for owners is simple: can the income stream hold up? DVY pays variable quarterly distributions sourced from dividends of roughly 100 U.S. companies screened for payout history and yield, and it currently throws off a trailing yield of ... Why Retirees Keep Buying This Dividend ETF After 22 Years of Payments

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.

Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and broaden patient access. The company has also granted Rigel Pharmaceuticals exclusive rights to commercialize VEPPANU, an FDA approved PROTAC based breast cancer therapy. These agreements reflect fresh moves in Pfizer's oncology R&D and commercialization approach that have not been covered in earlier updates. Pfizer's stock closed at $25.9, with the share price up 2.3%...

Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell short of the S&P 500’s 10.8% gain during that period.

The Invesco S&P 500 High Dividend Low Volatility ETF (NYSEARCA:SPHD) sends income to shareholders every month, with distributions rising roughly 23% in 2025 and 2026 monthly payouts climbing to around $0.208 per share, with a current 30-day SEC yield of 4.5%. The question is whether that income rests on a durable foundation or whether recent ... SPHD Pays Monthly Income Without Fail Since 2012; Here’s What Could Break the Streak

As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX.

Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street.